Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells.

Malec V, Coulson JM, Urbé S, Clague MJ.

J Proteome Res. 2015 Dec 4;14(12):5263-72. doi: 10.1021/acs.jproteome.5b00692. Epub 2015 Nov 16.

PMID:
26506913
2.

Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.

Leisz S, Schulz K, Erb S, Oefner P, Dettmer K, Mougiakakos D, Wang E, Marincola FM, Stehle F, Seliger B.

Oncotarget. 2015 May 10;6(13):11395-406.

4.

The VHL-dependent regulation of microRNAs in renal cancer.

Neal CS, Michael MZ, Rawlings LH, Van der Hoek MB, Gleadle JM.

BMC Med. 2010 Oct 21;8:64. doi: 10.1186/1741-7015-8-64.

5.

Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.

Ordóñez-Navadijo Á, Fuertes-Yebra E, Acosta-Iborra B, Balsa E, Elorza A, Aragonés J, Landazuri MO.

Oncogene. 2016 Feb 4;35(5):587-94. doi: 10.1038/onc.2015.113. Epub 2015 Apr 27.

PMID:
25915846
6.

The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells.

Razorenova OV, Castellini L, Colavitti R, Edgington LE, Nicolau M, Huang X, Bedogni B, Mills EM, Bogyo M, Giaccia AJ.

Mol Cell Biol. 2014 Feb;34(4):739-51. doi: 10.1128/MCB.00644-12. Epub 2013 Dec 16.

7.

Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins.

Rohan SM, Xiao Y, Liang Y, Dudas ME, Al-Ahmadie HA, Fine SW, Gopalan A, Reuter VE, Rosenblum MK, Russo P, Tickoo SK.

Mod Pathol. 2011 Sep;24(9):1207-20. doi: 10.1038/modpathol.2011.80. Epub 2011 May 20.

8.

NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.

Pantuck AJ, An J, Liu H, Rettig MB.

Cancer Res. 2010 Jan 15;70(2):752-61. doi: 10.1158/0008-5472.CAN-09-2211. Epub 2010 Jan 12.

9.

von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas.

Yi Y, Mikhaylova O, Mamedova A, Bastola P, Biesiada J, Alshaikh E, Levin L, Sheridan RM, Meller J, Czyzyk-Krzeska MF.

Clin Cancer Res. 2010 Nov 1;16(21):5142-52. doi: 10.1158/1078-0432.CCR-09-3416. Epub 2010 Oct 26.

10.

Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways.

Lichner Z, Mejia-Guerrero S, Ignacak M, Krizova A, Bao TT, Girgis AH, Youssef YM, Yousef GM.

Am J Pathol. 2012 Apr;180(4):1675-87. doi: 10.1016/j.ajpath.2011.12.030. Epub 2012 Feb 9.

PMID:
22326755
11.

Loss of PL6 protein expression in renal clear cell carcinomas and other VHL-deficient tumours.

Ivanova AV, Vortmeyer A, Ivanov SV, Nickerson ML, Maher ER, Lerman MI.

J Pathol. 2008 Jan;214(1):46-57.

PMID:
17973242
12.

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S.

Clin Cancer Res. 2013 Sep 15;19(18):5218-26. doi: 10.1158/1078-0432.CCR-13-0491. Epub 2013 Jul 23.

13.

Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.

Wiesener MS, Münchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jürgensen JS, Gruber G, Maxwell PH, Löning SA, Frei U, Maher ER, Gröne HJ, Eckardt KU.

Cancer Res. 2001 Jul 1;61(13):5215-22.

14.

Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.

Esteban MA, Tran MG, Harten SK, Hill P, Castellanos MC, Chandra A, Raval R, O'brien TS, Maxwell PH.

Cancer Res. 2006 Apr 1;66(7):3567-75.

15.

Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.

Gunningham SP, Currie MJ, Han C, Turner K, Scott PA, Robinson BA, Harris AL, Fox SB.

Cancer Res. 2001 Apr 1;61(7):3206-11.

16.

Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.

Luu VD, Boysen G, Struckmann K, Casagrande S, von Teichman A, Wild PJ, Sulser T, Schraml P, Moch H.

Clin Cancer Res. 2009 May 15;15(10):3297-304. doi: 10.1158/1078-0432.CCR-08-2779. Epub 2009 Apr 28.

17.

PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.

Petrella BL, Brinckerhoff CE.

Cancer Biol Ther. 2009 Jul;8(14):1389-401. Epub 2009 Jul 30.

18.

Proteomic analysis of signaling network regulation in renal cell carcinomas with differential hypoxia-inducible factor-2α expression.

Nagaprashantha LD, Talamantes T, Singhal J, Guo J, Vatsyayan R, Rauniyar N, Awasthi S, Singhal SS, Prokai L.

PLoS One. 2013 Aug 5;8(8):e71654. doi: 10.1371/journal.pone.0071654. Print 2013.

19.

Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.

Perier A, Fregni G, Wittnebel S, Gad S, Allard M, Gervois N, Escudier B, Azzarone B, Caignard A.

Oncogene. 2011 Jun 9;30(23):2622-32. doi: 10.1038/onc.2010.638. Epub 2011 Jan 24.

PMID:
21258414
20.

Supplemental Content

Support Center